RT Journal Article
SR Electronic
T1 COVID-19 in-hospital mortality and mode of death in a dynamic and non-restricted tertiary care model in Germany
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.22.20160127
DO 10.1101/2020.07.22.20160127
A1 Rieg, Siegbert
A1 Cube, Maja von
A1 Kalbhenn, Johannes
A1 Utzolino, Stefan
A1 Pernice, Katharina
A1 Bechet, Lena
A1 Baur, Johanna
A1 Lang, Corinna N.
A1 Wagner, Dirk
A1 Wolkewitz, Martin
A1 Kern, Winfried V.
A1 Biever, Paul
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/07/24/2020.07.22.20160127.abstract
AB Background Reported mortality of hospitalised COVID-19 patients varies substantially, particularly in critically ill patients. So far COVID-19 in-hospital mortality and modes of death under optimised care conditions have not been systematically studied.Methods This retrospective observational monocenter cohort study was performed after implementation of a non-restricted, dynamic tertiary care model at the University Medical Center Freiburg, an experienced ARDS and ECMO referral center. All hospitalised patients with PCR-confirmed SARS-CoV-2 infection were included. The primary endpoint was in-hospital mortality, secondary endpoints included major complications and modes of death. A multistate analysis and a Cox regression analysis for competing risk models were performed. Modes of death were determined by two independent reviewers.Results Between February 25, and May 8, 213 patients were included in the analysis. The median age was 65 years, 129 patients (61%) were male. 70 patients (33%) were admitted to the intensive care unit (ICU), of which 57 patients (81%) received mechanical ventilation and 23 patients (33%) extracorporeal membrane-oxygenation (ECMO) support. According to the multistate model the probability to die within 90 days after COVID-19 onset was 24% in the whole cohort. If the levels of care at time of study entry were accounted for, the probabilities to die were 16% if the patient was initially on a regular ward, 47% if in the ICU and 57% if mechanical ventilation was required at study entry. Age ≥65 years and male sex were predictors for in-hospital death. Predominant complications – as judged by two independent reviewers – determining modes of death were multi-organ failure, septic shock and thromboembolic and hemorrhagic complications.Conclusion In a dynamic care model COVID-19-related in-hospital mortality remained substantial. In the absence of potent antiviral agents, strategies to alleviate or prevent the identified complications should be investigated. In this context, multistate analyses enable comparison of models-of-care and treatment strategies and allow estimation and allocation of health care resources.Registration German Clinical Trials Register (identifier DRKS00021775), retrospectively registered June 10, 2020.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialDRKS00021775Funding StatementMVC was funded by the EQUIP programme of the Faculty of Medicine, University of Freiburg.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study and data collection were approved by the Institutional Review Board of the University Medical Center Freiburg (348/20) and was registered in the German Clinical Trials Register (identifier DRKS00021775). We followed the ethical standards set by the Helsinki Declaration of 1964, as revised in 2013, and the research guidelines of the University of Freiburg. The Institutional Review Board of the University Medical Center Freiburg considered the collection of routine data as evaluation of service and waived the need for written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe dataset analysed in this study is available from the corresponding author on reasonable request.List of abbreviationsCOVID-19Coronavirus disease 2019ECMOExtracorporeal membrane-oxygenationICUIntensive care unitBMIBody mass index BMIIDInfectious DiseasesMVMechanical ventilationSAPS2-scoreSimplified acute physiology score 2HRHazard ratio